The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Role of Catheter's Position for Final Results in Intrathecal Drug Delivery. Analysis Based on CSF Dynamics and Specific Drugs Profiles

  • De Andres, Jose (Anesthesia, Critical Care, and Multidisciplinary Pain Management Department, Valencia University General Hospital) ;
  • Perotti, Luciano (Anesthesia, Critical Care, and Multidisciplinary Pain Management Department, Valencia University General Hospital) ;
  • Villanueva, Vicente (Anesthesia, Critical Care, and Multidisciplinary Pain Management Department, Valencia University General Hospital) ;
  • Asensio Samper, Juan Marcos (Anesthesia, Critical Care, and Multidisciplinary Pain Management Department, Valencia University General Hospital) ;
  • Fabregat-Cid, Gustavo (Anesthesia, Critical Care, and Multidisciplinary Pain Management Department, Valencia University General Hospital)
  • Received : 2013.07.15
  • Accepted : 2013.08.21
  • Published : 2013.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

Intrathecal drug delivery is an effective and safe option for the treatment of chronic pathology refractory to conventional pain therapies. Typical intrathecal administered drugs are opioids, baclofen, local anesthetics and adjuvant medications. Although knowledge about mechanisms of action of intrathecal drugs are every day more clear many doubt remain respect the correct location of intrathecal catheter in order to achieve the best therapeutic result. We analyze the factors that can affect drug distribution within the cerebrospinal fluid. Three categories of variables were identified: drug features, cerebrospinal fluid (CSF) dynamics and patients features. First category includes physicochemical properties and pharmacological features of intrathecal administered drugs with special attention to drug lipophilicity. In the second category, the variables in CSF flow, are considered that can modify the drug distribution within the CSF with special attention to the new theories of liquoral circulation. Last category try to explain inter-individual difference in baclofen response with difference that are specific for each patients such as the anatomical area to treat, patient posture or reaction to inflammatory stimulus. We conclude that a comprehensive evaluation of the patients, including imaging techniques to study the anatomy and physiology of intrathecal environment and CSF dynamics, could become essential in the future to the purpose of optimize the clinical outcome of intrathecal therapy.

Keywords

References

  1. Ochs G, Naumann C, Dimitrijevic M, Sindou M. Intrathecal baclofen therapy for spinal origin spasticity: spinal cord injury, spinal cord disease, and multiple sclerosis. Neuromodulation 1999; 2: 108-19.
  2. Avellino AM, Loeser JD. Intrathecal baclofen for the treatment of intractable spasticity of spine or brain etiology. Neuromodulation 2000; 3: 75-81. https://doi.org/10.1046/j.1525-1403.2000.00075.x
  3. Burns AS, Meythaler JM. Intrathecal baclofen in tetraplegia of spinal origin: efficacy for upper extremity hypertonia. Spinal Cord 2001; 39: 413-9. https://doi.org/10.1038/sj.sc.3101178
  4. Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320: 1517-21. https://doi.org/10.1056/NEJM198906083202303
  5. Plassat R, Perrouin Verbe B, Menei P, Menegalli D, Mathe JF, Richard I. Treatment of spasticity with intrathecal Baclofen administration: long-term follow-up, review of 40 patients. Spinal Cord 2004; 42: 686-93. https://doi.org/10.1038/sj.sc.3101647
  6. Deer TR, Prager J, Levy R, Rathmell J, Buchser E, Burton A, et al. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2012; 15: 436-64. https://doi.org/10.1111/j.1525-1403.2012.00476.x
  7. Hayek SM, Deer TR, Pope JE, Panchal SJ, Patel VB. Intrathecal therapy for cancer and non-cancer pain. Pain Physician 2011; 14: 219-48.
  8. De Andres J, Asensio-Samper JM, Fabregat-Cid G. Advances in intrathecal drug delivery. Curr Opin Anaesthesiol 2013 [in press].
  9. Kim JH, Jung JY, Cho MS. Continuous intrathecal morphine administration for cancer pain management using an intrathecal catheter connected to a subcutaneous injection port: a retrospective analysis of 22 terminal cancer patients in Korean population. Korean J Pain 2013; 26: 32-8. https://doi.org/10.3344/kjp.2013.26.1.32
  10. Erdine S, De Andres J. Drug delivery systems. Pain Pract 2006; 6: 51-7. https://doi.org/10.1111/j.1533-2500.2006.00059.x
  11. Loubser PG, Narayan RK, Sandin KJ, Donovan WH, Russell KD. Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury. Paraplegia 1991; 29: 48-64. https://doi.org/10.1038/sc.1991.7
  12. Dario A, Tomei G. A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf 2004; 27: 799-818. https://doi.org/10.2165/00002018-200427110-00004
  13. Francisco GE. The role of intrathecal baclofen therapy in the upper motor neuron syndrome. Eura Medicophys 2004; 40: 131-43.
  14. Deer TR, Prager J, Levy R, Burton A, Buchser E, Caraway D, et al. Polyanalgesic Consensus Conference--2012: recommendations on trialing for intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2012; 15: 420-35. https://doi.org/10.1111/j.1525-1403.2012.00450.x
  15. Albright AL, Thompson K, Carlos S, Minnigh MB. Cerebrospinal fluid baclofen concentrations in patients undergoing continuous intrathecal baclofen therapy. Dev Med Child Neurol 2007; 49: 423-5. https://doi.org/10.1111/j.1469-8749.2007.00423.x
  16. Miele VJ, Price KO, Bloomfield S, Hogg J, Bailes JE. A review of intrathecal morphine therapy related granulomas. Eur J Pain 2006; 10: 251-61. https://doi.org/10.1016/j.ejpain.2005.05.002
  17. Bernards CM. Recent insights into the pharmacokinetics of spinal opioids and the relevance to opioid selection. Curr Opin Anaesthesiol 2004; 17: 441-7. https://doi.org/10.1097/00001503-200410000-00015
  18. Flack SH, Anderson CM, Bernards C. Morphine distribution in the spinal cord after chronic infusion in pigs. Anesth Analg 2011; 112: 460-4. https://doi.org/10.1213/ANE.0b013e318203b7c0
  19. Rhee SM, Choi EJ, Lee PB, Nahm FS. Catheter obstruction of intrathecal drug administration system -a case report-. Korean J Pain 2012; 25: 47-51. https://doi.org/10.3344/kjp.2012.25.1.47
  20. Hassenbusch S, Burchiel K, Coffey RJ, Cousins MJ, Deer T, Hahn MB, et al. Management of intrathecal catheter-tip inflammatory masses: a consensus statement. Pain Med 2002; 3: 313-23. https://doi.org/10.1046/j.1526-4637.2002.02055.x
  21. Deer TR, Levy R, Prager J, Buchser E, Burton A, Caraway D, et al. Polyanalgesic Consensus Conference--2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain. Neuromodulation 2012; 15: 467-82. https://doi.org/10.1111/j.1525-1403.2012.00486.x
  22. Wang JK, Nauss LA, Thomas JE. Pain relief by intrathecally applied morphine in man. Anesthesiology 1979; 50: 149-51. https://doi.org/10.1097/00000542-197902000-00013
  23. Deer TR, Raso LJ, Garten TG. Inflammatory mass of an intrathecal catheter in patients receiving baclofen as a sole agent: a report of two cases and a review of the identification and treatment of the complication. Pain Med 2007; 8: 259-62. https://doi.org/10.1111/j.1526-4637.2006.00150.x
  24. Yaksh TL, Hassenbusch S, Burchiel K, Hildebrand KR, Page LM, Coffey RJ. Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data. Pain Med 2002; 3: 300-12. https://doi.org/10.1046/j.1526-4637.2002.02048.x
  25. De Andres J, Tatay Vivo J, Palmisani S, Villanueva Perez VL, Minguez A. Intrathecal granuloma formation in a patient receiving long-term spinal infusion of tramadol. Pain Med 2010; 11: 1059-62. https://doi.org/10.1111/j.1526-4637.2010.00885.x
  26. Peng P, Massicotte EM. Spinal cord compression from intrathecal catheter-tip inflammatory mass: case report and a review of etiology. Reg Anesth Pain Med 2004; 29: 237-42.
  27. Allen JW, Horais KA, Tozier NA, Yaksh TL. Opiate pharmacology of intrathecal granulomas. Anesthesiology 2006; 105: 590-8. https://doi.org/10.1097/00000542-200609000-00025
  28. De Andres J, Palmisani S, Villanueva Perez VL, Asensio J, Lopez-Alarcon MD. Can an intrathecal, catheter-tip-associated inflammatory mass reoccur? Clin J Pain 2010; 26: 631-4. https://doi.org/10.1097/AJP.0b013e3181e4a541
  29. Narouze SN, Casanova J, Souzdalnitski D. Patients with a history of spine surgery or spinal injury may have a higher chance of intrathecal catheter granuloma formation. Pain Pract 2013 [in press].
  30. Michael A, Buffen E, Rauck R, Anderson W, McGirt M, Mendenhall HV. An in vivo canine study to assess granulomatous responses in the MedStream Programmable Infusion System (TM) and the SynchroMed II Infusion System(R). Pain Med 2012; 13: 175-84. https://doi.org/10.1111/j.1526-4637.2011.01308.x
  31. Cusato M, Allegri M, Niebel T, Ingelmo P, Broglia M, Braschi A, et al. Flip-flop kinetics of ropivacaine during continuous epidural infusion influences its accumulation rate. Eur J Clin Pharmacol 2011; 67: 399-406. https://doi.org/10.1007/s00228-010-0927-x
  32. Reina MA, Franco CD, Lopez A, De Andres JA, van Zundert A. Clinical implications of epidural fat in the spinal canal. A scanning electron microscopic study. Acta Anaesthesiol Belg 2009; 60: 7-17.
  33. Ummenhofer WC, Arends RH, Shen DD, Bernards CM. Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil. Anesthesiology 2000; 92: 739-53. https://doi.org/10.1097/00000542-200003000-00018
  34. Rosow CE, Dershwitz M. Pharmacology of opioid analgesics. In: Anesthesiology. Edited by Longnecker DE, Brown DL, Newman MF, Zapol WM. New York (NY), McGraw-Hill. 2008, pp 869-96.
  35. Eisenach JC, Hood DD, Curry R, Shafer SL. Cephalad movement of morphine and fentanyl in humans after intrathecal injection. Anesthesiology 2003; 99: 166-73. https://doi.org/10.1097/00000542-200307000-00027
  36. Gogia V, Chaudhary P, Ahmed A, Khurana D, Mishra S, Bhatnagar S. Intrathecal morphine pump for neuropathic cancer pain: a case report. Am J Hosp Palliat Care 2012; 29: 409-11. https://doi.org/10.1177/1049909111419650
  37. Goodchild CS, Nadeson R, Cohen E. Supraspinal and spinal cord opioid receptors are responsible for antinociception following intrathecal morphine injections. Eur J Anaesthesiol 2004; 21: 179-85.
  38. Deer TR, Prager J, Levy R, Rathmell J, Buchser E, Burton A, et al. Polyanalgesic Consensus Conference--2012: consensus on diagnosis, detection, and treatment of catheter-tip granulomas (inflammatory masses). Neuromodulation 2012; 15: 483-95. https://doi.org/10.1111/j.1525-1403.2012.00449.x
  39. Georges P, Lavand'homme P. Intrathecal hydromorphone instead of the old intrathecal morphine: the best is the enemy of the good? Eur J Anaesthesiol 2012; 29: 3-4.
  40. Waara-Wolleat KL, Hildebrand KR, Stewart GR. A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain. Pain Med 2006; 7: 251-9. https://doi.org/10.1111/j.1526-4637.2006.00155.x
  41. Heavner JE. Pharmacology of local anesthetics. In: Anesthesiology. Edited by Longnecker DE, Brown DL, Newman MF, Zapol WM. New York (NY), McGraw-Hill. 2008, pp 954-73.
  42. Kumru H, Stetkarova I, Schindler C, Vidal J, Kofler M. Neurophysiological evidence for muscle tone reduction by intrathecal baclofen at the brainstem level. Clin Neurophysiol 2011; 122: 1229-37. https://doi.org/10.1016/j.clinph.2010.09.010
  43. Natale M, Mirone G, Rotondo M, Moraci A. Intrathecal baclofen therapy for severe spasticity: analysis on a series of 112 consecutive patients and future prospectives. Clin Neurol Neurosurg 2012; 114: 321-5. https://doi.org/10.1016/j.clineuro.2011.10.046
  44. Uchiyama T, Nakanishi K, Fukawa N, Yoshioka H, Murakami S, Nakano N, et al. Neuromodulation using intrathecal baclofen therapy for spasticity and dystonia. Neurol Med Chir (Tokyo) 2012; 52: 463-9. https://doi.org/10.2176/nmc.52.463
  45. Bahl A, Tripathi C, McMullan J, Goddard J. Novel use of intrathecal baclofen drug delivery system for periodic focal dystonia in a teenager. Neuromodulation 2013; 16: 273-5. https://doi.org/10.1111/j.1525-1403.2012.00510.x
  46. Turner M, Nguyen HS, Cohen-Gadol AA. Intraventricular baclofen as an alternative to intrathecal baclofen for intractable spasticity or dystonia: outcomes and technical considerations. J Neurosurg Pediatr 2012; 10: 315-9. https://doi.org/10.3171/2012.6.PEDS11456
  47. Chiodo AE, Saval A. Intrathecal baclofen for the treatment of spinal myoclonus: a case series. J Spinal Cord Med 2012; 35: 64-7. https://doi.org/10.1179/2045772311Y.0000000006
  48. Hoarau X, Richer E, Dehail P, Cuny E. A 10-year follow-up study of patients with severe traumatic brain injury and dysautonomia treated with intrathecal baclofen therapy. Brain Inj 2012; 26: 927-40. https://doi.org/10.3109/02699052.2012.661913
  49. van der Plas AA, van Rijn MA, Marinus J, Putter H, van Hilten JJ. Efficacy of intrathecal baclofen on different pain qualities in complex regional pain syndrome. Anesth Analg 2013; 116: 211-5. https://doi.org/10.1213/ANE.0b013e31826f0a2e
  50. Schmidtko A, Lotsch J, Freynhagen R, Geisslinger G. Ziconotide for treatment of severe chronic pain. Lancet 2010; 375: 1569-77. https://doi.org/10.1016/S0140-6736(10)60354-6
  51. Alicino I, Giglio M, Manca F, Bruno F, Puntillo F. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice. Pain 2012; 153: 245-9. https://doi.org/10.1016/j.pain.2011.10.002
  52. Dupoiron D, Bore F, Lefebvre-Kuntz D, Brenet O, Debourmont S, Dixmerias F, et al. Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol. Pain Physician 2012; 15: 395-403.
  53. Lawson EF, Wallace MS. Advances in intrathecal drug delivery. Curr Opin Anaesthesiol 2012; 25: 572-6. https://doi.org/10.1097/ACO.0b013e3283572319
  54. Wallace M, Yaksh TL. Characteristics of distribution of morphine and metabolites in cerebrospinal fluid and plasma with chronic intrathecal morphine infusion in humans. Anesth Analg 2012; 115: 797-804. https://doi.org/10.1213/ANE.0b013e3182645dfd
  55. Bernards CM. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology 2006; 105: 169-78. https://doi.org/10.1097/00000542-200607000-00027
  56. Loubser PG, Narayan RK. Effect of subarachnoid catheter position on the efficacy of intrathecal baclofen for spinal spasticity. Anesthesiology 1993; 79: 611-4. https://doi.org/10.1097/00000542-199309000-00028
  57. Flack SH, Bernards CM. Cerebrospinal fluid and spinal cord distribution of hyperbaric bupivacaine and baclofen during slow intrathecal infusion in pigs. Anesthesiology 2010; 112: 165-73. https://doi.org/10.1097/ALN.0b013e3181c38da5
  58. Henry-Feugeas MC, Idy-Peretti I, Baledent O, Poncelet-Didon A, Zannoli G, Bittoun J, et al. Origin of subarachnoid cerebrospinal fluid pulsations: a phase-contrast MR analysis. Magn Reson Imaging 2000; 18: 387-95. https://doi.org/10.1016/S0730-725X(99)00142-3
  59. Hsu Y, Hettiarachchi HD, Zhu DC, Linninger AA. The frequency and magnitude of cerebrospinal fluid pulsations influence intrathecal drug distribution: key factors for interpatient variability. Anesth Analg 2012; 115: 386-94. https://doi.org/10.1213/ANE.0b013e3182536211
  60. Martin BA, Reymond P, Novy J, Balédent O, Stergiopulos N. A coupled hydrodynamic model of the cardiovascular and cerebrospinal fluid system. Am J Physiol Heart Circ Physiol 2012; 302: H1492-509. https://doi.org/10.1152/ajpheart.00658.2011
  61. Prats-Galino A, Reina MA, Puigdellivol-Sanchez A, Juanes Mendez JA, De Andres JA, Collier CB. Cerebrospinal fluid volume and nerve root vulnerability during lumbar puncture or spinal anaesthesia at different vertebral levels. Anaesth Intensive Care 2012; 40: 643-7.
  62. Sivakumar G, Yap Y, Tsegaye M, Vloeberghs M. Intrathecal baclofen therapy for spasticity of cerebral origin--does the position of the intrathecal catheter matter? Childs Nerv Syst 2010; 26: 1097-102. https://doi.org/10.1007/s00381-010-1124-z
  63. McCall TD, MacDonald JD. Cervical catheter tip placement for intrathecal baclofen administration. Neurosurgery 2006; 59: 634-40. https://doi.org/10.1227/01.NEU.0000227570.40402.77
  64. Deer TR, Raso LJ, Coffey RJ, Allen JW. Intrathecal baclofen and catheter tip inflammatory mass lesions (granulomas): a reevaluation of case reports and imaging findings in light of experimental, clinicopathological, and radiological evidence. Pain Med 2008; 9: 391-5. https://doi.org/10.1111/j.1526-4637.2008.00468.x

Cited by

  1. A numerical investigation of intrathecal isobaric drug dispersion within the cervical subarachnoid space vol.12, pp.3, 2017, https://doi.org/10.1371/journal.pone.0173680
  2. Numerical study of intrathecal drug delivery to a permeable spinal cord: effect of catheter position and angle vol.20, pp.15, 2017, https://doi.org/10.1080/10255842.2017.1393805
  3. The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks vol.20, pp.2, 2017, https://doi.org/10.1111/ner.12579
  4. Risk management in intrathecal analgesia: safely using a well-established therapy vol.4, pp.2, 2014, https://doi.org/10.2217/pmt.14.5
  5. Intrathecal baclofen pump implantation for complex regional pain syndrome in a patient with a spinal cord stimulator: consideration about optimal location of intrathecal catheter tip - A case report - vol.13, pp.2, 2013, https://doi.org/10.17085/apm.2018.13.2.201
  6. Intrathecal drug delivery for pain management: recent advances and future developments vol.16, pp.8, 2019, https://doi.org/10.1080/17425247.2019.1642870
  7. Baclofen pump with pre-brainstem catheter tip placement: technical note and case series vol.37, pp.1, 2021, https://doi.org/10.1007/s00381-020-04679-3
  8. Evaluation of the Effect of Intranasal Lidocaine in the Treatment of Spasticity in Patients with Traumatic Brain Injury vol.11, pp.4, 2013, https://doi.org/10.5812/aapm.115849